biostudies-literatureUnknown227(2)Nyombayire JWellcome Trust<h4>Background</h4>From 2019 to 2021, Rwandan residents of the border with the Democratic Republic of the Congo were offered the Ad26.ZEBOV (adenovirus type 26 vector vaccine encoding Ebola virus glycoprotein) and MVA-BN-Filo (modified vaccinia virus Ankara vector vaccine, encoding glycoproteins from Ebola, Sudan, Marburg, and nucleoprotein from Tai Forest viruses) Ebola vaccine regimen.<h4>Methods</h4>Nonpregnant persons aged ≥2 years were eligible. Unsolicited adverse events (UAEs) were reported through phone calls or visits, and serious adverse events (SAEs) were recorded per International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use guidelines.<h4>Results</h4>Following Ad26.ZEBOV, UAEs were reported by 0.68% of 216 113 vaccinees and were more coThe Journal of infectious diseases268-277https://www.ebi.ac.uk/biostudies/studies/S-EPMC9833427biostudies-literatureMonitoring of Adverse Events in Recipients of the 2-Dose Ebola Vaccine Regimen of Ad26.ZEBOV Followed by MVA-BN-Filo in the UMURINZI Ebola Vaccination Campaign.PMC9833427Karita EKatwere MTichacek AIngabire RNyombayire JMagod BNoben JMazarati JBSayinzoga FMazzei AHammoud NPriddy FRobinson CNsanzimana SAllen SParker RWall KMfalseMonitoring of Adverse Events in Recipients of the 2-Dose Ebola Vaccine Regimen of Ad26.ZEBOV Followed by MVA-BN-Filo in the UMURINZI Ebola Vaccination Campaign.<h4>Background</h4>From 2019 to 2021, Rwandan residents of the border with the Democratic Republic of the Congo were offered the Ad26.ZEBOV (adenovirus type 26 vector vaccine encoding Ebola virus glycoprotein) and MVA-BN-Filo (modified vaccinia virus Ankara vector vaccine, encoding glycoproteins from Ebola, Sudan, Marburg, and nucleoprotein from Tai Forest viruses) Ebola vaccine regimen.<h4>Methods</h4>Nonpregnant persons aged ≥2 years were eligible. Unsolicited adverse events (UAEs) were reported through phone calls or visits, and serious adverse events (SAEs) were recorded per International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use guidelines.<h4>Results</h4>Following Ad26.ZEBOV, UAEs were reported by 0.68% of 216 113 vaccinees and were more co2023-01-01T00:00:00Z2023 Jan2025-04-04T14:30:13.791Z2025-04-04T14:30:13.791ZS-EPMC98334273577614010.1093/infdis/jiac283